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The Role of CD247 Polymorphisms in Bulgarian  
Patients with Systemic Lupus Erythematosus
ABSTRACT Decreased expression of the tCR ζ-chain has been reported 
in several autoimmune and inflammatory diseases. Recent evidence sug-
gests that this deficiency may be due to polymorphisms in the CD247 
gene. A total 52 patients with systemic lupus erythematosus (Sle) and 
95 healthy controls of Bulgarian ethnicity were genotyped for 837C>g, 
rs1052230, 844A>t, and rs1052231 using a taqMan genotyping assay. 
None of the two polymorphisms appeared associated with the diseases. 
On the other hand, we have found that the -837gg genotype and the g 
allele were associated with hematological disease. the -844AA genotype 
and the A allele appeared associated with the hematological disease as 
well. the -843AA genotype and the A allele were found to be associated 
with antinuclear antibody (ANA) tests and immunological disease. An 
association was found between the -837g allele and arthritis. the Ag 
haplotype was found to be associated with hematological disease, ANA, 
and immunological disease. Our preliminary data confirm the previous 
findings that the CD247 polymorphisms are mainly associated with the 
clinical outcome of the disease and less with susceptibility.
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INTRODUCTION
Systemic lupus erythematosus (Sle) is a chronic 
autoimmune disease with a serious prognosis, char-
acterized by the production of autoantibodies affect-
ing various organs and systems. Some of the con-
firmed genetic alterations in Sle affect t-cells, while 
the ability of t-lymphocytes to establish an immune 
response is primarily associated with the t-cell re-
ceptor (tCR) (1). the tCR is a multi-subunit complex, 
comprising at least eight transmembrane units. the 
clonotypic tCR α- and β-chains are responsible for the 
antigen recognition (2), while the invariant chains of 
the CD3 complex (δ, ε, and γ) and two ζ polypeptides 
couple antigen recognition to downstream signal 
transduction pathways. Studies of t-cells from tCR ζ-
deficient mice showed that the ζ-chain is essential for 
the assembly and surface expression of the tCR/CD3 
complex (3). Since tCR ζ is expressed by NK cells as 
a component of the activating receptors NK cell pro-
tein 46, NK protein 30, and CD16 (fcγRiii, low-affinity 
fc receptor for igg) we can hypothesize that changes 
in tCR ζ expression could have profound effects on 
innate as well as adaptive immune responses (4,5).
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the CD247 gene is composed of eight exons sep-
arated by distances of between 0.7 and 8 kb (6,7). the 
coding region of the CD247 gene has been found to 
be non-polymorphic (8). A detailed analysis of 3’UtR 
showed that the 837C>g, rs1052230, 844A>t, and 
rs1052231 polymorphisms are associated with low 
tCR ζ expression (9). the two variants of CD247 3’-
UtR may reduce tCR ζ mRNA stability, resulting in tCR 
ζ down-regulation.
the aim of the present study was to analyze the 
genetic variants of CD247 as risk factors for the sus-




fifty-two patients with systemic lupus erythema-
tosus were included in this study (45 women and 7 
men). the mean age was 40, with a range of 15 to 
78 years. the patients were followed for a mean of 
10 years at the Department of Nephrology, Medical 
University of Sofia. All the patients with Sle met the 
American College of Rheumatology (ACR) criteria. 
Ninety-five anonymous non-related healthy in-
dividuals, matched for sex, age, and ethnicity with 
the patients, were included for genetic analysis. they 
were selected from the Bio Bank of the Molecular 
Medicine Center and National genetic laboratory.
Genetic analysis
the study was carried out in accordance with 
the Code of ethics of the World Medical Association 
(Declaration of Helsinki) for experiments involving 
humans. the study was approved by the local ethics 
committee at the Medical University-Sofia. All par-
ticipants signed informed consent, and venous blood 
was drawn for DNA isolation. genomic DNA was ex-
tracted from the peripheral blood with the Chema-
gen DNA purification kit (Chemagen Ag).
the analysis of C247 polymorphisms 837C>g, 
rs1052230, 844A>t, and rs1052231 was performed 
using a taqMan genotyping assay.
Statistical Analysis
Allele and genotype frequencies were compared 
between Sle cases and controls using fisher’s exact 
test to calculate P values for 2×2 tables. Where sig-
nificant, data were expressed as P values and odds ra-
tios (OR) with exact 95% confidence intervals (Ci). the 
test for Hardy-Weinberg equilibrium was done using 
χ2 statistics.
RESULTS
the demographic and clinical data are presented 
in table 1. the two polymorphisms were in Hardy-
Weinberg equilibrium and in lD 0.75. None of them 
appeared associated with the diseases (table 2), but 
they appeared to be associated with its clinical ex-
pression (table 3). We found the -837gg genotype 
and the g allele were associated with hematological 
disease (P=0.004, OR 13, 95% Cl 1.5-109.5; P=0.004, 
OR 10.9, 95%Ci 1.4-86.7). the -844AA genotype and 
the A allele appeared associated with hematological 
disease as well (P=0.0003, OR 21.5, 95% Ci 2.6-180.7; 
P=0.0005, OR 15.3, 95%Ci 1.9-119.5). the -843AA gen-
otype and the A allele were found to be associated 
with antinuclear antibodies (ANA) (P=0.007, OR 5.8, 
95% Cl 1.6-21; P=0.02, OR 3.1, 95%Ci 1.1-8.9) and im-
munological disease (P=0.03; OR 3.8, 95% Ci 1.1-12.5, 
P=0.02; OR 3.1, 95% Ci 1.1-8.8). An association was 
found between the -837g allele and arthritis (P=0.04; 
OR 3.1, 95%Ci 1-9.4). the Ag haplotype was found to 
Table 1. Demographic and clinical data





































Sle: systemic lupus erythematosus; SD: Standard Deviation; eMg: electromyography; ANA: antinuclear antibodies
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be associated with hematological disease (P=0.003), 
ANA (P=0.05) and immunological disease (P=0.05).
(11). Our results also confirmed the findings that the 
two polymorphisms do not confer any risk for the de-
velopment of the disease. However, the CD3Z -844 
AA+At genotypes are found to be associated with 
the development of Sle in women (13). An associa-
tion was found between a haplotype carrying the 
two low-expression variants and Sle (9). According 
to the same authors, the CD247 3’-UtR SNPs may be 
associated with the severity rather than with the dis-
ease risk markers (9). in agreement with that observa-
tion, we have found the two polymorphisms associ-
ated with the clinical expression of Sle such as arthri-
tis, hematological disease, ANA, and immunological 
disease. Our results confirm earlier findings that that 
low-secreting CD247 alleles and genotypes are as-
sociated with hematologic disorders, oral ulcers, and 
anti-ds DNA antibody production (10). 
CONCLUSIONS
the major limitation of the present study was the 
limited number of patients analyzed. Nevertheless, 
our preliminary data confirm the previous findings 
that the CD247 polymorphisms are mainly associ-
ated with the clinical outcome of the disease and less 
with susceptibility. furthermore, a recent study dem-
onstrated that CD247 expression can serve as a bio-
marker for assessing the effect of chemotherapeutic 
and biological drugs for the treatment of subjects suf-
fering from a chronic inflammatory condition (14).
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Table 2. genotype and allele frequencies of CD247 
837C>g and 844A>t polymorphisms among pa-
tients with systemic lupus erythematosus (Sle) 
and controls
Table 3. Comparison between the genotypes and ACR criteria for systemic lupus erythematosus (Sle)





































































































NS: Not significant; dsDNA: antibodies to double stranded DNA; SM: anti-Smith antibodies; APA: antiphospholipid antibod-
ies; ANA: antinuclear antibodies
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DISCUSSION
the expression of CD247 was studied recently and 
was found to be significantly lower in patients with 
Sle than in healthy controls (11,12). the two SNPs, 
rs1052230 and rs1052231, in the 3’UtR of the gene 
were found to affect the CD247 expression level in 
both patients with Sle and healthy controls. Despite 
that, no association was found between the individ-
ual polymorphisms and the development of Sle in 
european (9), Chinese (11), and multiethnic cohorts 
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